| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Actinogen Medical is an Australian clinical stage biotechnology company. The company is focused on the treatment of Alzheimer's Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer’s and dementia. |
| Category: | Health & biotech |
| URL: | http://www.actinogen.com.au |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | ACW |
| Year of Commencement: | |
| Address: | 2/1 Walker Avenue, West Perth WA 6005 |
| State: | Western Australia |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | https://www.facebook.com/actinogenmedical |
| Linkedin: | https://www.linkedin.com/company/actinogen-medical |
| Key Personnel: | |
| Validated Problem Solver Engagements: |
No items found
|
| Awards won: | |
| Current Period Rank: |
| WA Annual Rank 2016: | 84 |
Milestones:
Appointed George Morstyn as non-executive director August, 2017 Enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease March, 2017 Appointed Geoff Brooke as chairperson February, 2017 Received UK approval to conduct its Phase II clinical trial of Xanamem January, 2017 US FDA has approved Actinogen Medical's investigational new drug application to initiate XanADu |
Funding:
|
|
Company News:
NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking
| Amount Seeking: | |
| Type of capital raise: | |
| Pre-money valuation: | |
| ESIC Status: | |
| ESIC Upload: | |
| Future Intentions: | |
| Investment Video: | |
| Investment Pitchdeck: | |
| Investment URL: | |
| Investment Phone: | |
| Investment Email: |